Floatz logo

Mozobil

Children Cancer, Solid Tumor

University Hospital, Clermont-FerrandPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Children Cancer, Solid Tumor cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Tianjin Medical University Cancer Institute and Hospital
Phase 2BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB
Nivolumab
Australian & New Zealand Children's Haematology/Oncology Group
Phase 2B
Irinotecan
Australian & New Zealand Children's Haematology/Oncology Group
Phase 1/2B
Carboplatin
Samsung Medical Center
Phase 2B

View all 50 →

Same molecule, other indications

Mozobil is also rated in:

plasma cell myelomaDormant
CCC
Indicative ·
48 / 100
View asset →
metastatic carcinoma in the boneDormant
CC
Indicative ·
43 / 100
View asset →
osteosarcomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →